lilotomab lilotomab lilotomab (formerly tetulomab, hh1) is a murine monoclonal antibody against cd37, a glycoprotein which is expressed on the surface of mature human b cells. it was generated at the norwegian radium hospital. lilotomabmonoclonal antibodytypewhole antibodysourcemousetargetcd37clinical dataother namestetulomab, hh1atc codenoneidentifierscas number1453362-55-4 1453362-90-7 (lutetium (177lu) lilotomab satetraxetan)chemspidernoneunii58i6ynr7bvkeggd12125 as of 2016 it was under development by the norwegian company nordic nanovector asa as a radioimmunotherapeutic in which lilotomab is conjugated to the beta radiation-emitting isotope lutetium-177 by means of a linker called satetraxetan, a derivative of dota. this compound is called 177lu-hh1 or lutetium (177lu) lilotomab satetraxetan (trade name betalutin). as of 2016, a phase 1/2 clinical trial in people with non-hodgkin lymphoma was underway. the satetraxetan structure chelating lutetium-177